Fresenius Kabi South Africa Professional Information Leaflets

Browse all SAHPRA-approved professional information leaflets for the Fresenius Kabi South Africa manufacturer.

All
Searching...

Moxifloxacin 400 Mg/250 Ml Fresenius 400 mg/250 mL Solution for infusion

S
Fresenius Kabi South Africa
Moxifloxacin

Dipeptiven 100 mL Concentrate for solution for infusion.

S
Fresenius Kabi South Africa
N(2)-L-Alanyl-L-Glutamine

Ondansetron 4 Mg/2 Ml Fresenius, Ondansetron 8 Mg/4 Ml Fresenius 4 mg/2 ml, 8 mg/4 ml Solution for injection or infusion

S
Fresenius Kabi South Africa
Ondansetron

Paclitaxel 30 Mg/5 Ml Fresenius, Paclitaxel 100 Mg/16,7 Ml Fresenius, Paclitaxel 300 Mg/50 Ml Fresenius, 30 mg/5 ml, 100 mg/16,7 ml, 300 mg/50 ml Concentrate for solution for infusion

S
Fresenius Kabi South Africa
Paclitaxel

Palonosetron 0,05 Mg/Ml Fresenius 0,05 mg/mL Solution for injection

S
Fresenius Kabi South Africa
Palonosetron

Paracetamol 10 Mg/Ml (50 Ml) Fresenius, Paracetamol 10 Mg/Ml (100 Ml) Fresenius 10 mg/mL (50 mL), 10 mg/mL (100 mL) Solution for infusion

S
Fresenius Kabi South Africa
Paracetamol

Paracetamol Fresenius 50 ml,100 ml Solution for intravenous infusion

S
Fresenius Kabi South Africa
Paracetamol

Pemetrexed 500 Mg/20 Ml Fresenius 500 mg Concentrate for solution for infusion

S
Fresenius Kabi South Africa
Pemetrexed

Piperacillin/Tazobactam 2 G/0,25 G Fresenius. Piperacillin/Tazobactam 4 G/0,5 G Fresenius 2 g/0,25 g & 4 g/0,5 g Powder for solution for infusion

S
Fresenius Kabi South Africa
Piperacillin And Tazobactam Sodium

Piperacillin/Tazobactam Fresenius 2 g/0,25 g AND 4 g/0,5 g Powder for solution for infusion

S
Fresenius Kabi South Africa
Piperacillin Tazobactam

Potassium Chloride 15 % Flexivial Fresenius 100 mL Concentrate for solution for infusion.

S
Fresenius Kabi South Africa
Potassium Chloride

Propofol 1 % Ps Fresenius 10 mg per mL Emulsion for injection or infusion in pre-filled syringe

S
Fresenius Kabi South Africa
Propofo
App Icon

Medinsert Mobile App

3000+ Package Inserts on the go.

VIEW